Datasheet

APO-E Antibody
CATALOG NUMBER: 7333

Availability: In stock

$0.00
Product Price Options

* Required Fields

$0.00
Specifications
Properties
Additional Info
Background

Specifications

SPECIES REACTIVITY:Human, Mouse, Rat
HOMOLOGY:Predicted species reactivity based on immunogen sequence: Pig: (78%)
TESTED APPLICATIONS:ELISA, IF, IHC-P, WB
APPLICATIONS:APO-E antibody can be used for detection of APO-E by Western blot at 1 - 2 μg/mL. Antibody can also be used for immunohistochemistry starting at 5 μg/mL. For immunofluorescence start at 20 μg/mL.
USER NOTE:Optimal dilutions for each application to be determined by the researcher.
POSITIVE CONTROL:1) Cat. No. 1303 - Human Brain Tissue Lysate
 2) Cat. No. 10-201 - Human Liver Tissue Slide
PREDICTED MOLECULAR WEIGHT:Predicted: 35 kDa

Observed: 34 kDa
IMMUNOGEN:APO-E antibody was raised against a 19 amino acid peptide near the carboxy terminus of human APO-E.

The immunogen is located within amino acids 220 - 270 of APO-E.
HOST SPECIES:Rabbit

Properties

PURIFICATION:APO-E Antibody is affinity chromatography purified via peptide column.
PHYSICAL STATE:Liquid
BUFFER:APO-E Antibody is supplied in PBS containing 0.02% sodium azide.
CONCENTRATION:1 mg/mL
STORAGE CONDITIONS:APO-E antibody can be stored at 4˚C for three months and -20˚C, stable for up to one year.
CLONALITY:Polyclonal
ISOTYPE:IgG
CONJUGATE:Unconjugated

Additional Info

ALTERNATE NAMES:APO-E Antibody: AD2, LPG, LDLCQ5, Apolipoprotein E, Apo-E
ACCESSION NO.:NP_000032
PROTEIN GI NO.:4557325
OFFICIAL SYMBOL:APOE
GENE ID:348

Background

BACKGROUND:APO-E Antibody: Chylomicron remnants and very low density lipoprotein (VLDL) remnants are rapidly removed from the circulation by receptor-mediated endocytosis in the liver. Apolipoprotein E (APO-E), a main apoprotein of the chylomicron, binds to a specific receptor on liver cells and peripheral cells and is essential for the normal catabolism of triglyceride-rich lipoprotein constituents. Defects in APO-E result in familial dysbetalipoproteinemia, or type III hyperlipoproteinemia (HLP III), in which increased plasma cholesterol and triglycerides are the consequence of impaired clearance of chylomicron and VLDL remnants.
REFERENCES: 1) Vasquez EC, Peotta VA, Gava TMC, et al. Cardiac and vascular phenotypes in the epolipoprotein E-deficient mouse. J. Biomed. Sci. 2012; 19:22.
2) Feussner G, Funke H, Weng W, et al. Severe type III hyperlipoproteinemia associated with unusual apolipoprotein E1 phenotype and epsilon 1/’null’ genotype. Eur. J. Clin. Invest. 1992; 22:599-608.

For Research Use Only